<DOC>
	<DOC>NCT00117039</DOC>
	<brief_summary>The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network (NCCN) guidelines).</brief_summary>
	<brief_title>A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects with nonmyeloid malignancy Anemia (Hgb less than 11.0 g/dL) due to cancer chemotherapy Receiving chemotherapy and expected to receive at least 8 additional weeks of chemotherapy Adequate renal function Adequate liver function Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or myelodysplastic syndromes (MDS) Unstable cardiac disease Active bleeding Active systemic or chronic infection Severe active chronic inflammatory disease Other hematologic disorder associated with anemia Uncontrolled hypertension Known iron or nutritional deficiency Known positive test for human immunodeficiency virus (HIV) infection History of pure red cell aplasia History of positive antibody response to any erythropoietic agent Erythropoietin therapy within 4 weeks before screening RBC transfusions within 2 weeks prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>anemia</keyword>
	<keyword>fatigue</keyword>
	<keyword>Aranesp®</keyword>
	<keyword>clinical trial</keyword>
</DOC>